생체고분자를 이용한 천식치료제의 경피 투과 전달 시스템 연구

Abstract

Tulobuterol is a drug for the treatment of bronchial asthma and chronic obstructive bronchial disease mainly in European nations. The transdermal route of application offers considarable advantages especially for the treatment of chronic disease: whereas multidose oral application often leads to unwanted fluctuations of plasma drug levels, transdermal application allows plasma levels to be kept constant over the application period. So, the transdermal route is specially interested in potent β-adrenoceptor agonist such as Tulobuterol. Recently many forward nations have developed transdermal dosage forms containing therapeutic agents such as scopolamine, nitroglycerin, estradiol, clonidine, fentanyl, etc. Also, in domestic, some companies have developed patches of antiinflammatory drugs, but the development is not by their own technique and most of marketed products were imported. Therefore, if we develop an novel transdermal dosage forms containing Tulobuterol, it makes a contribution to the trade gain and the incresement in the power of scientific technologies.